Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

J Neuroinflammation · 2017 · PMC5577769 · PMID 28859672

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Following cessation of laquinimod treatment on day 28, slanDC depletion showed a trend of recovery (Fig. 3 ) in day 42 (washout) samples.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.